Acrivon Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from Acrivon Therapeutics, Inc. ( (ACRV) ).

On June 13, 2025, Acrivon Therapeutics, Inc. held its annual meeting of stockholders, where 94.59% of the outstanding shares were represented. During the meeting, stockholders elected three Class III directors to serve until the 2028 annual meeting and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ACRV) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Spark’s Take on ACRV Stock

According to Spark, TipRanks’ AI Analyst, ACRV is a Underperform.

Acrivon Therapeutics, Inc. faces major financial challenges, including no revenue, increasing losses, and negative cash flows, leading to a low overall score. The weak technical indicators further compound these concerns. However, recent corporate events, such as advancements in clinical programs and an extended cash runway, offer some optimism for future prospects. Investors should be cautious due to the company’s current financial instability.

To see Spark’s full report on ACRV stock, click here.

More about Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of precision oncology therapeutics. The company aims to create targeted treatments for cancer patients by leveraging its proprietary platform to identify and develop therapies that address specific molecular drivers of cancer.

Average Trading Volume: 772,751

Technical Sentiment Signal: Sell

Current Market Cap: $39.82M

Find detailed analytics on ACRV stock on TipRanks’ Stock Analysis page.